Navigation Links
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
Date:6/3/2009

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer -

- 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer -

- 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cancer -

- Data in All Three Studies Surpassed Pre-Established Criteria for Expansion of Patient Enrollment -

- Positive Initial Data across Indications and Chemotherapy Regimens Suggests Bavituximab Could Have Broad Anti-Cancer Utility -

TUSTIN, Calif., June 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today highlighted the progress that the company has achieved in its Phase II program assessing the combination of bavituximab and chemotherapy in three separate cancer trials. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body's own immune system to recognize and act on the tumor and its supporting blood vessels, resulting in anti-cancer effects. Bavituximab is currently being tested in combination with chemotherapy in one Phase II trial in advanced lung cancer and two Phase II trials in advanced breast cancer. Recently-reported data highlights from these studies include the following:

    -- Non-Small Cell Lung Cancer:  Bavituximab in Combination with
       Carboplatin and Paclitaxel
       In the Phase II trial evaluating bavituximab in combination with
       carboplatin and paclitaxel in non-small cell lung cancer (NSCLC)
       patients with locally advanced or metastatic disease, 11 of 17, or
       almost 65% of evaluable patients in the initial cohort of 21 patients
       achieved an objective tumor response. These early results, which
       exceeded the pre-specified endpoint needed to expand the tria
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015  Eli Lilly and Company (NYSE: ... Diego (UCSD) of its intent to end its contract ... Treatment in Asymptomatic Alzheimer,s disease (A4) study. The A4 ... the preclinical stage of Alzheimer,s disease in older individuals ... a PET scan, but do not show symptoms of ...
(Date:8/4/2015)... 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... Sangamo,s executive vice president, research and development, will provide ... ® development programs and an overview of the ... 11, 2015, at the 2015 Wedbush Pacgrow Healthcare Conference. ... York, NY . The presentation will ...
(Date:8/4/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases, ... second quarter ended June 30, 2015 and provided a ... eight XmAb® antibody candidates are in clinical testing, ... momentum of this pipeline of antibodies is a ...
Breaking Medicine Technology:Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study 2Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study 3Sangamo BioSciences Announces Presentation At The 2015 Wedbush Pacgrow Healthcare Conference 2Xencor Reports Second Quarter 2015 Financial and Operating Results 2Xencor Reports Second Quarter 2015 Financial and Operating Results 3Xencor Reports Second Quarter 2015 Financial and Operating Results 4Xencor Reports Second Quarter 2015 Financial and Operating Results 5Xencor Reports Second Quarter 2015 Financial and Operating Results 6Xencor Reports Second Quarter 2015 Financial and Operating Results 7Xencor Reports Second Quarter 2015 Financial and Operating Results 8Xencor Reports Second Quarter 2015 Financial and Operating Results 9
(Date:8/4/2015)... ... August 04, 2015 , ... Angelina Jolie is in it at age ... every year. Dr. Angela DeRosa, DO, MBA, CPE aka “Dr. Hot Flash,” ... scary unknown out of menopause. , Myth #1: Menopause only affects old ladies. ...
(Date:8/4/2015)... ... , ... School is almost back in session. Parents and children are enjoying ... scramble. Dublin, OH family dentist , Dr. Cheung (of BrightSmile Dental) reminds parents ... In fact, the dentist recently updated the practice’s surgical suite to prepare for nervous ...
(Date:8/4/2015)... ... 2015 , ... Many men are confused about the safety of testosterone replacement ... as a voice of authority for men seeking accurate information about testosterone. , ... and expertise in the safe and effective treatment of low testosterone. In recent years, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye ... entering kindergarten. All required immunizations are covered for members under the Healthchek program ... who aren’t caught up with their immunizations may not be allowed to attend ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... announced that Bruce McCalley joins its executive leadership team as Senior Vice President ... success at technology companies and expanding global markets with a special emphasis on ...
Breaking Medicine News(10 mins):Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 2Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 4Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... specialist makes a difference, study finds , WEDNESDAY, Aug. 22 ... to see the doctor who diagnoses their melanoma, the more ... -- skin cancer at the time of diagnosis, a new ... poorer patients getting diagnosed with thicker melanomas, the researchers said. ...
... the brain, study suggests , , WEDNESDAY, Aug. 22 (HealthDay ... frightening, traumatic memories go so deep and linger so ... rats shows that a powerful neurochemical called norepinephrine is ... but it also "imprints" an emotional fear tagged to ...
... weak or unsubstantiated, review finds , TUESDAY, Aug. 21 (HealthDay ... disease often lack proper documentation or validation, experts report in ... American Medical Association . , A team of researchers in ... They found that 286 (66.2 percent) of these claims were ...
... Fried, baked food compound poses no threat, major study finds ... be little or no link between breast cancer and acrylamide, ... to the largest epidemiological study on the subject conducted to ... acrylamide in the diet does not appear to be an ...
... in Taiwan has shown that an 800-year-old formula, Four-Agents ... pain after three cycles of treatment; however, a beneficial ... dosage regimen and treatment length used in this study ... published in the August 15 issue of the online, ...
... A computer bug infected Web gamers, with ominous results, ... Online role-playing games could provide insight into how infectious ... the real world, American researchers report. , A programming ... ("corrupted blood") among virtual characters in the popular online ...
Cached Medicine News:Health News:Melanoma Diagnosis Often Delayed for Rural Poor 2Health News:Study Probes Roots of Fearful Memories 2Health News:Gene Studies of Male-Female Differences Often Flawed 2Health News:Acrylamide Won't Raise Breast Cancer Risk 2Health News:Acrylamide Won't Raise Breast Cancer Risk 3Health News:Acrylamide Won't Raise Breast Cancer Risk 4Health News:Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea? 2Health News:Online 'Epidemic' Gives Clues to Bird Flu Spread 2
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
... explanation of foldable intraocular lenses. The instrument ... placed under the implant and divides the ... helps support both halves of the lens ... in the anterior chamber is avoided. The ...
Medicine Products: